Compare FT & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FT | MOLN |
|---|---|---|
| Founded | 1988 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.8M | 144.0M |
| IPO Year | N/A | 2021 |
| Metric | FT | MOLN |
|---|---|---|
| Price | $8.12 | $4.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 32.5K | 3.5K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 7.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $318.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.83 | $3.36 |
| 52 Week High | $8.35 | $5.36 |
| Indicator | FT | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 53.59 | 41.81 |
| Support Level | $7.82 | $4.04 |
| Resistance Level | $8.24 | $4.51 |
| Average True Range (ATR) | 0.10 | 0.17 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 70.86 | 35.65 |
Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.